DESTINY-Lung04: T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
Primary results from DESTINY-Lung04, a global phase 3 registrational trial, were presented at the IASLC World Conference on Lung Cancer 2026 in Seoul, South Kor...
View MoreWCLC 2026
REZILIENT 3: Zipalertinib Plus Chemotherapy Improves PFS in EGFR Exon 20+ NSCLC
Results from the phase 3 REZILIENT 3 trial, presented at the 2026 World Conference on Lung Cancer, show that adding zipalertinib to platinum-based chemotherapy ...
View More
Latest Conference News
EVOKE-03 Misses PFS Endpoint for SG Plus Pembrolizumab in NSCLC
Primary results from the phase 3 EVOKE-03/KEYNOTE D46 trial, presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lu...
View More
MAVERICK Supports MRI Surveillance Without PCI in SCLC
Results from the SWOG S1827 MAVERICK phase III trial, presented at the IASLC World Conference on Lung Cancer 2026 in Seoul, South Korea, indicate that brain MRI...
View More
ADAURA: Osimertinib Improves 8-Year Survival in EGFR-Mutated NSCLC
An exploratory 8-year overall survival (OS) landmark analysis of the phase III ADAURA trial, presented at the 2026 World Conference on Lung Cancer, provides the...
View More
ASTRES Reports 54.9% 12-Month PFS With Atezolizumab
Final analysis data from ASTRES (EudraCT 2021-002695-40), a Phase 2 single-arm study, demonstrate that consolidation atezolizumab achieved a 12-month progressio...
View More
NAUTIKA1: Neoadjuvant Divarasib Shows Activity in KRAS G12C+ NSCLC
Updated data from the phase II NAUTIKA1 trial (NCT04302025) presented at the 2026 World Conference on Lung Cancer demonstrate that neoadjuvant divarasib, an ora...
View More
B7-H3 Is Highly Expressed but Not Prognostic in ES-SCLC
A biomarker analysis of tumor samples from two landmark first-line extensive-stage small-cell lung cancer (ES-SCLC) trials, IMpower133 and SKYSCRAPER-02, reveal...
View More
SOHO-01 Identifies HER2 T862A in Sevabertinib Resistance
An exploratory biomarker analysis of the Phase 1/2 SOHO-01 trial (NCT05099172) has identified secondary HER2 T862A substitution as the predominant genomic mecha...
View More